NEW YORK, October 5, 2021 / PRNewswire / – Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investments in healthcare and industrial companies, today announced that it has completed a majority recapitalization of BioIVT, Inc. ( “BioIVT”) with Linden Capital Partners (“Linden”), a Chicagoprivate equity company in the health sector. Terms of the transaction were not disclosed.
Based at Westbury, New York, BioIVT is the market leader in providing critical biological samples and value-added services for the academic research, pharmaceutical research and diagnostic and discovery and development markets.
Gene Gorbach, an Arsenal investment partner, said: “We are proud to have partnered with the talented team at BioIVT to create a company that supports tens of thousands of scientists around the world. BioIVT’s products and services allow scientists to more accurately determine the effectiveness and safety of new therapies and, in doing so, minimize risks and optimize the effectiveness of subsequent research. We are happy to continue to support this important mission as continued investors in the company. ”
“We are delighted to have worked with the talented management team and employees of BioIVT to execute an ambitious growth strategy to build a market-leading company,” said Dave spaight, an Arsenal operating partner who has served as executive chairman of BioIVT for the past five years. “BioIVT is uniquely positioned to facilitate the safe and effective advancement of research to bring therapies and diagnostics to all whose health and well-being are supported by advances in science and clinical care. “
Jeff Gatz, CEO of BioIVT, said: “We are grateful to Arsenal for their strategic and operational support in helping us significantly expand our capabilities in achieving our mission of elevating science. We are delighted with our new partnership with Linden and delighted that Arsenal continues to be involved with BioIVT. “
Jefferies LLC and Perella Weinberg Partners served as financial advisers to BioIVT. Kirkland and Ellis LLP served as legal counsel to BioIVT.
BioIVT is a leading provider of critical biological samples for the pharmaceutical and diagnostic discovery and development market. The company specializes in control and disease state samples, including tissue, immune cell products, blood and other biofluids. BioIVT’s clinical sample portfolio directly supports precision medicine research and efforts to improve patient outcomes by coupling comprehensive clinical data with donor samples. For more information, please visit www.bioivt.com.
About Arsenal Capital Partners
Arsenal is a leading private equity firm specializing in investments in mid-market and healthcare companies. Since its creation in 2000, Arsenal has raised institutional investment funds of $ 5.3 billion, has made more than 200 platform and extension investments and achieved more than 30 achievements. The company works with management teams to create strategically important companies that have a positive impact on the healthcare industry. For more information, please visit www.arsenalcapital.com.
Brian schaffer / Kristen duarte
[email protected] / [email protected]
SOURCE Arsenal Capital Partners